0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-03-31 Sage Accounts Production Advanced 2023 - FRS102_2023 674,151 674,151 674,151 xbrli:pure xbrli:shares iso4217:GBP 10169702 2023-03-31 2024-03-30 10169702 2024-03-30 10169702 2023-03-30 10169702 2022-03-31 2023-03-30 10169702 2023-03-30 10169702 2022-03-30 10169702 bus:Director1 2023-03-31 2024-03-30 10169702 core:AfterOneYear 2024-03-30 10169702 core:AfterOneYear 2023-03-30 10169702 core:WithinOneYear 2024-03-30 10169702 core:WithinOneYear 2023-03-30 10169702 core:ShareCapital 2024-03-30 10169702 core:ShareCapital 2023-03-30 10169702 core:SharePremium 2024-03-30 10169702 core:SharePremium 2023-03-30 10169702 core:RetainedEarningsAccumulatedLosses 2024-03-30 10169702 core:RetainedEarningsAccumulatedLosses 2023-03-30 10169702 core:CostValuation core:Non-currentFinancialInstruments 2024-03-30 10169702 core:Non-currentFinancialInstruments 2024-03-30 10169702 core:Non-currentFinancialInstruments 2023-03-30 10169702 bus:Director1 2022-03-30 10169702 bus:Director1 2023-03-30 10169702 bus:Director1 2022-03-31 2023-03-30 10169702 bus:SmallEntities 2023-03-31 2024-03-30 10169702 bus:AuditExempt-NoAccountantsReport 2023-03-31 2024-03-30 10169702 bus:SmallCompaniesRegimeForAccounts 2023-03-31 2024-03-30 10169702 bus:PrivateLimitedCompanyLtd 2023-03-31 2024-03-30 10169702 bus:FullAccounts 2023-03-31 2024-03-30
COMPANY REGISTRATION NUMBER: 10169702
SNAITH DENTAL CARE LIMITED
Filleted Unaudited Financial Statements
30 March 2024
SNAITH DENTAL CARE LIMITED
Statement of Financial Position
30 March 2024
2024
2023
Note
£
£
Fixed assets
Investments
4
674,151
674,151
Current assets
Cash at bank and in hand
3,911
1,090
Creditors: amounts falling due within one year
5
23,845
22,909
--------
--------
Net current liabilities
19,934
21,819
---------
---------
Total assets less current liabilities
654,217
652,332
Creditors: amounts falling due after more than one year
6
251,429
265,710
---------
---------
Net assets
402,788
386,622
---------
---------
Capital and reserves
Called up share capital
2
2
Share premium account
299,998
299,998
Profit and loss account
102,788
86,622
---------
---------
Shareholders funds
402,788
386,622
---------
---------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 30 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
SNAITH DENTAL CARE LIMITED
Statement of Financial Position (continued)
30 March 2024
These financial statements were approved by the board of directors and authorised for issue on 31 July 2024 , and are signed on behalf of the board by:
Dr A O'Brien
Director
Company registration number: 10169702
SNAITH DENTAL CARE LIMITED
Notes to the Financial Statements
Year ended 30 March 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 113 Union Street, Oldham, Lancashire, OL1 1RU.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Investments
Shares in group undertakings
£
Cost
At 31 March 2023 and 30 March 2024
674,151
---------
Impairment
At 31 March 2023 and 30 March 2024
---------
Carrying amount
At 30 March 2024
674,151
---------
At 30 March 2023
674,151
---------
5. Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
20,202
20,202
Trade creditors
1,199
1,201
Corporation tax
1,873
1,435
Other creditors
571
71
--------
--------
23,845
22,909
--------
--------
6. Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
109,207
123,488
Amounts owed to group undertakings and undertakings in which the company has a participating interest
142,222
142,222
---------
---------
251,429
265,710
---------
---------
7. Director's advances, credits and guarantees
During the year the director entered into the following advances and credits with the company:
2024
Balance brought forward
Advances/ (credits) to the director
Amounts repaid
Balance outstanding
£
£
£
£
Dr A O'Brien
----
----
----
----
2023
Balance brought forward
Advances/ (credits) to the director
Amounts repaid
Balance outstanding
£
£
£
£
Dr A O'Brien
( 11)
47,740
( 47,800)
( 71)
----
--------
--------
----
8. Related party transactions
The company was under the control of Mr O'Brien throughout the current period.